Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery

Inclusion Criteria: * The age was 18-75 years old, and the gender was not limited; * The clinical diagnosis of angina pectoris or angina pectoris equivalent symptoms (attack at least twice a week), Within 1 year, coronary CTA or coronary angiography examination of coronary artery normal or lesions \< 50%; * Willing to follow up and sign informed consent. Exclusion Criteria: * Patients were selected and had no angina pectoris without medication * History of vascular reconstruction within 6 months, CABG or PCI; * Preparation for CABG or PCI during the trial period * The maximum lesions of major branches of major vessels were ≥ 50% in CTA or angiographic examination; * Severe cardiovascular and pulmonary vascular diseases: stubborn heart failure or cardiogenic shock, hypertrophic obstructive cardiomyopathy, severe aortic stenosis, incomplete closure, aortic dissection, pulmonary embolism; * There were three months of acute myocardial infarction; * Severe respiratory disease, COPD or active pulmonary infection; * Although the patients with poor blood pressure control were treated with hypertension, the hypertension was not controlled and / or systolic pressure ≥ 180mmhg and diastolic pressure ≥ 110mmhg before the end of screening period; * Severe liver and kidney diseases, such as liver and kidney dysfunction (alt, AST ≥ 1.5 times of the upper limit of normal value, Cr \> 1.5 times of normal value), active liver disease, cirrhosis or uremia patients; * Any other serious diseases or conditions such as malignant tumor, severe anemia, severe renal artery stenosis, severe anxiety depression (HAMD-17) and suicide or maniac mental illness; * Participated in other clinical studies within 30 days before the selection, or is currently participating in other clinical studies; * Pregnant, lactating women and women and men with recent birth plans; * Allergic constitution or allergy to known components of the study drug; * The researchers judged that the patients who were not suitable for the study were not suitable. (Note: patients need to stop using other cardiovascular traditional Chinese patent medicines and simple preparations or traditional Chinese medicine for 7 days before enrollment.)